- Details
- Description
Packaging Size:
1Bottle/Box
Strength:
10ml:100mg
Composition:
Tislelizumab
Treatment:
Esophageal Cancer
Form:
Injection
Brand:
百泽安 (Tevimbra)
Quantity Unit:
10ml:100mg/Bottle/Box
Manufacturer:
BeiGene Biotechnology,china
Tevimbra (Tislelizumab-jsgr) sold under the brand name 百泽安 in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
